Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies, Inc. is trading at $6.24, up 0.48% on the session. The 50 day average sits at $6.07 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 47.4, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $5.31 with resistance near $5.98, so that band frames the current range. Average daily movement is roughly $0.40, or about 6.4% of the share price, which is what any stop placement has to allow for. The overall health score of 51 out of 100 combines a trend score of 48, momentum of 66 and a risk score of 36.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.